LifeTech Scientific Corporation
先健科技公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1302)

VOLUNTARY ANNOUNCEMENT

Enrollment in the Phase III Clinical Study of IBS® Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System Completed

This announcement is made by LifeTech Scientific Corporation (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide its shareholders and potential investors with information in relation to the latest business and new product development of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that on 7 July 2023, the enrollment of the self-developed IBS® Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System ("**IBS® Coronary Scaffold**" or the "**Product**") in the China Prospective Multicenter Single-arm Clinical Study (the "**Phase III Clinical Study**") was completed.

The Phase III Clinical Study is a crucial component of the confirmatory clinical study of the Product in China. It was officially launched in February 2023 and it has completed the enrollment of more than 800 subjects in total only after five months. The operation success rate is 100%. Up to now, no device-related serious adverse events (SAE) have occurred. At this point, the enrollment of the confirmatory clinical study of the Product in China has completed, and it has fully entered the clinical follow-up stage. After reaching the primary endpoint, the application for marketing approval will be submitted in China.

The Chinese confirmatory clinical study of IBS® Coronary Scaffold was approved in August 2021. According to the guidelines issued by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (the "**NMPA**"), it is divided into two parts: randomized controlled study (phase II clinical study) and single-arm objective performance criteria study (phase III clinical study), aiming to evaluate the safety and effectiveness of IBS® Coronary Scaffold in patients with coronary heart disease. The confirmatory clinical study of IBS® Coronary Scaffold in China was conducted by Academician Gao Runlin as the principal investigator (PI), with Academicians Ge Junbo, Han Yaling and clinical experts from around 40 clinical research centers all over the country fully participating. Previously, the Phase II clinical study successfully completed all the enrollment of 518 subjects in nine months, with an operation success rate of 100%. All patients had completed six-month follow-up, and no device-related serious adverse events (SAE) occurred.

IBS® Coronary Scaffold is the world's first fully degradable iron-based absorbable coronary scaffold, as far as the Company is aware. The backbone is processed from high-purity nitrided iron pipes with high strength and plasticity, and having strong supporting force and ultrathin strut thickness. The innovative material research and unique technological path enable the Product to retain the advantages of complete specifications, superior mechanical properties, good biocompatibility, and simple operation of permanent metal coronary stents, as well as fully absorbable characteristics, effectively avoiding a series of long-term prognosis issues that may arise from the implantation of permanent metal stents.

The successful enrollment in the Phase III Clinical Study will push the Chinese confirmatory clinical research of the Product to the next significant research stage. Currently, IBS® Coronary Scaffold has been successfully submitted for CE registration approval and is expected to become the second successfully commercialized iron-based absorbable scaffold product in European Union, following the IBS Angel™ Iron Bioresorbable Scaffold System. With the steady advancement of follow-up clinical trials, there are expected to be more evidence-based medical evidences to further confirm the safety and effectiveness of the Product. The Company believes that when it is launched to market, IBS® Coronary Scaffold will bring unprecedented treatment for patients with coronary heart disease all over the world.

By order of the Board
LifeTech Scientific Corporation
XIE Yuehui
Executive Director, Chairman and Chief Executive Officer

Hong Kong, 10 July 2023

As at the date of this announcement, the Board comprises Mr. XIE Yuehui and Mr. LIU Jianxiong being executive Directors; Mr. JIANG Feng being non-executive Director; and Mr. LIANG Hsien Tse Joseph, Mr. WANG Wansong and Mr. ZHOU Luming being independent non-executive Directors.